樂觀
$13.97
情境價格
$23.550
+0.009 (+0.04%)收盤時
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.
KeyBanc
$30
2026-08-06
KeyBanc
2026-08-06
目標價
$30
Citi
$34
2026-08-06
Citi
2026-08-06
目標價
$34
Morgan Stanley
$26
2026-07-22
Morgan Stanley
2026-07-22
目標價
$26
TD Cowen
$32
2026-06-18
TD Cowen
2026-06-18
目標價
$32
Morgan Stanley
$23
2026-05-15
Morgan Stanley
2026-05-15
目標價
$23
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Wall Street's Latest Ratings Overview

Elanco Animal Health Addresses Year-Round Pet Health Needs

Elanco's Pet Health Business Accelerates Growth Amid Seasonal Changes

Elanco to Announce Q3 2026 Financial Results on November 6

Elanco to Announce Q3 2026 Financial Results on November 6
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Elanco Animal Health Inc is a good buy right now due to its current price of $23.55, which is significantly lower than the median analyst price target of $32, indicating a potential upside of 31.3%. Additionally, the company's gross margin has improved to 48.17% in Q2 2026, reflecting strong operational efficiency. However, a risk to consider is the negative net income reported in Q4 2025 of -276 million USD, which highlights ongoing profitability challenges.
11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。